January 20, 1999

Revaccination of High-Risk Adults With Pneumococcal Polysaccharide Vaccine

Author Affiliations

Author Affiliations: Minneapolis Veterans Affairs Medical Center and University of Minnesota, Minneapolis.

JAMA. 1999;281(3):280-281. doi:10.1001/jama.281.3.280

Pneumococcal disease accounts for approximately 500,000 cases of pneumonia, 50,000 cases of bacteremia, and 40,000 deaths each year.1 Vaccination of adults with the pneumococcal polysaccharide vaccine has not been convincingly demonstrated to reduce the risk for pneumonia among groups currently targeted for vaccination2 but is associated with substantial reductions in invasive disease.1 Among the elderly, vaccination is not only cost-effective but cost saving for the prevention of bacteremia.3 Few other diagnostic or therapeutic interventions can make such a claim.

First Page Preview View Large
First page PDF preview
First page PDF preview